secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2022-03-04T23:59:59+00:00
Accession:  0000950170-22-002873
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics CSO David Dornan resigns, stays as consultant for 6 months
-------------------------------------------------------------------------------

- David Dornan, Ph.D. resigned as Chief Scientific Officer effective March 11, 2022.
- Entered consulting agreement for 6 months at $500/hour to assist transition.
- Outstanding equity awards will continue to vest during consulting period.
- Consultant reports to CEO Randall Schatzman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017022002873/0000950170-22-002873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017022002873/bolt-20220301.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer